Prednisolone
- Generic Name
- Prednisolone
- Brand Names
- Millipred Dp 6 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28O5
- CAS Number
- 50-24-8
- Unique Ingredient Identifier
- 9PHQ9Y1OLM
- Background
Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.
Prednisolone was granted FDA approval on 21 June 1955.
- Indication
Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- -
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Not Applicable
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 358
- Registration Number
- NCT00417014
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Not Applicable
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 353
- Registration Number
- NCT00416377
Treatment of Acute Lymphoblastic Leukemia in Children
Phase 3
Completed
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00384306
- Locations
- 🇬🇧
GSK Clinical Trials Call Centre, Cambridge, United Kingdom
A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00379990
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00380133
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, Lancashire, United Kingdom
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT00379574
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷Asan Medical Cener, Seoul, Korea, Republic of
Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 90
- Registration Number
- NCT00379730
- Locations
- 🇿🇦
GSK Investigational Site, Mowbray, South Africa
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Not Applicable
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 550
- Registration Number
- NCT00343369
- Locations
- 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪Universitaets - Kinderklinik, Leipzig, Germany
Corticosteroids in the Treatment of Tuberculous Pleurisy
Not Applicable
Completed
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2008-08-26
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 1500
- Registration Number
- NCT00338793
- Locations
- 🇨🇳
Huan-Zhong Shi, Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath